Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arvinas Inc (NQ: ARVN )

31.77 -0.13 (-0.41%)
Streaming Delayed Price Updated: 12:57 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arvinas Inc

< Previous 1 2 3 4 5 6 Next >
Why Arvinas (ARVN) Shares Are Seeing Blue Skies
Arvinas Inc (NASDAQ: ARVN) shares are trading higher by 11.2% to $24.32 Monday morning after the company announced an oversubscribed $350 million private placement. 
Via Benzinga
Arvinas Announces Oversubscribed $350 Million Private Placement
From Arvinas Inc.
Via GlobeNewswire
Azenta Reports Upbeat Earnings, Joins Talis Biomedical, Sally Beauty And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 500 points on Tuesday. Shares of Azenta, Inc. (NASDAQ: AZTA) rose on Tuesday after the company reported better-than-expected fourth-quarter... 
Via Benzinga
Topics Stocks
Exposures US Equities
Analyst Ratings for Arvinas
Via Benzinga
Analyst Expectations for Arvinas's Future
Via Benzinga
Where Arvinas Stands With Analysts
Via Benzinga
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page 
Via Benzinga
Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC
From Arvinas Inc.
Via GlobeNewswire
7 Analysts Have This to Say About Arvinas
Via Benzinga
Barclays Maintains Overweight Rating for Arvinas: Here's What You Need To Know
Via Benzinga
Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
From Arvinas Inc.
Via GlobeNewswire
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
From Arvinas Inc.
Via GlobeNewswire
What 8 Analyst Ratings Have To Say About Arvinas
Via Benzinga
6 Analysts Have This to Say About Arvinas
Via Benzinga
Looking Into Arvinas's Return On Capital Employed
Via Benzinga
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer
Designation indicates entry into the U.K.’s Innovative Licensing and Access Pathway (ILAP) 
From Arvinas Inc.
Via GlobeNewswire
Where Arvinas Stands With Analysts
Via Benzinga
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
Collaboration expands Carrick’s clinical-stage Oncology program 
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
Arvinas Announces Changes to its Board of Directors
From Arvinas Inc.
Via GlobeNewswire
Arvinas Releases Early Cut Data Showing Encouraging Efficacy In Prostate Cancer With Certain Mutations
Arvinas Inc (NASDAQ: ARVN) announced interim data from its Phase 1/2 dose escalation and expansion trial of ARV-766 in metastatic  
Via Benzinga
Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Warner Bros. Discovery To Rally Around 62%? Here Are 10 Other Analyst Forecasts For Monday
Wells Fargo raised the price target for Stanley Black & Decker, Inc. (NYSE: SWK) from $85 to $90. Wells Fargo analyst Joe O'Dea maintained an Equal-Weight rating. Stanley Black & Decker shares rose 3%... 
Via Benzinga
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
From Arvinas Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.